Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.33 |
| ▸ | GALR1 | P47211 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963772 | 0.86 | AKR1B1 (0.33) | SLC6A4SLC6A3AKR1B1PDE7AGALR1 | |
| SCHEMBL5001009 | 0.85 | GALR1 (0.33) | AKR1B1PDE7AGALR1ALDH1A1 | |
| SCHEMBL5963305 | 0.83 | SLC6A3 (0.39) | SLC6A4SLC6A3AKR1B1PDE7AALDH1A1 | |
| SCHEMBL5964210 | 0.81 | AKR1B1 (0.34) | SLC6A4SLC6A3AKR1B1ALDH1A1LMNA | |
| SCHEMBL6820261 | 0.81 | FPR2 (0.35) | AKR1B1PDE7AALDH1A1LMNACYP3A4 | |
| SCHEMBL5007459 | 0.80 | FPR2 (0.32) | AKR1B1FPR2 | |
| SCHEMBL5004858 | 0.80 | AKR1B1 (0.33) | SLC6A4SLC6A3AKR1B1GALR1FPR2 | |
| SCHEMBL5964279 | 0.79 | AKR1B1 (0.31) | SLC6A4SLC6A3AKR1B1SLC6A2 | |
| SCHEMBL5963749 | 0.79 | FPR2 (0.34) | SLC6A4SLC6A3AKR1B1ALDH1A1LMNA | |
| SCHEMBL5963823 | 0.79 | GALR1 (0.35) | SLC6A4SLC6A3AKR1B1PDE7AGALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125840-B2 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1326851-B1 | SUBSTITUTED DIPEPTIDES AS GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | GHSR, GHRHR, SSTR4 | SLC6A4 794/4885SLC6A3 981/4885AKR1B1 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.